retatrutide diabetes trial Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist produced significant weight loss and A1c reduction in people What is Retatrutide? Key Facts

SeekPeptides has compiled the most current clinical data and community protocols into one resource so you can make an informed decision about whether this transition makes sense for your research goals

At a stable maintenance dose, most patients report significantly reduced GI symptoms after 48 weeks

Read the article: Institute for Health Transformation Diabetes WA Diabetes Victoria Diabetes Australia Bernard Kwadwo Yeboah Asiamah-Asare, PhD Suzanne Robinson To view or add a comment, sign in 134,603 followers

Some people experience mild side effects while taking semaglutide or tirzepatide, like nausea, digestive changes, or temporary injection-site discomfort

Prior Authorizations: Worth the Hassle

Although the proportion of such users is still tiny (less than 0.4%), the upward trend is clearly visible in the prescription data